Company: IOBT
Filing Date: 2025-07-24
Form Type: S-3
Source: 0001193125-25-164495
Chunk: 13

Company: IO Biotech, Inc.
Filing Date: 2025-07-24
Form: S-3
Chunk 13
---
ylembio®, IO112, IO170 or any other product candidate, if approved by the relevant regulatory bodies; |

| • |     | our ability to successfully commercialize Cylembio®,                                                                    
 IO112, IO170 or any other product candidates we may identify and pursue, if approved by the relevant regulatory bodies; |

7

| • |     | our ability to successfully establish or maintain collaborations or strategic relationships for our product 
 candidates;                                                                                                 |

| • |     | the rate and degree of market acceptance of Cylembio®,                                                                  
 IO112, IO170 or any other product candidates we may identify and pursue, if approved by the relevant regulatory bodies; |

| • |     | our ability to obtain orphan drug designation, Breakthrough Therapy Designation (BTD), accelerated or other 
 approval for any product candidates we may identify;                                                        |

| • |     | our expectations regarding government and third-party payor coverage and reimbursement; |

| • |     | our ability to manufacture, including through contract manufacturing organizations (CMOs), Cylembio®, IO112, IO170 or any other product candidate in conformity with the Food and Drug Administration’s (FDA’s) requirements and the requirements of other applicable regulatory authorities; |

| • |     | our ability to successfully build a sales force and commercial infrastructure; |

| • |     | our ability to compete with companies currently producing or engaged in the clinical development of treatments 
 for the disease indications that we pursue and treatment modalities that we develop;                           |

| • |     | our reliance on third parties to conduct our clinical trials; |

| • |     | our reliance on third-party CMOs to manufacture and supply our product candidates for us; |

| • |     | our ability to retain and recruit key personnel; |

| • |     | our ability to obtain and maintain intellectual property protection for Cylembio®, IO112, IO170 or any other product candidates we may identify and pursue; |

| • |     | our estimates of our expenses, ongoing losses, future revenue, capital requirements and our needs for or ability 
 to obtain additional financing;                                                                                  |

| • |     | our expectations regarding the time during which we will be an emerging growth company (EGC) under the Jumpstart 
 Our Business Startups Act (JOBS Act);                                                                            |

| • |     | our financial performance; |

| • |     | the effect of significant public health emergencies or geopolitical events on any of the foregoing or any other 
 aspects of